Ensitrelvir
Code | Size | Price |
---|
TAR-T9716-10mg | 10mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T9716-25mg | 25mg | £163.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Ensitrelvir is an orally active inhibitor of SARS-CoV-2 3CL protease with IC50 of 13 nM.
CAS:
2647530-73-0
Formula:
C22H17ClF3N9O2
Molecular Weight:
531.88
Pathway:
Microbiology/Virology
Purity:
0.9957
SMILES:
Cn1nc(cc(c(/N=C(NC(N2Cc3nn(C)cn3)=O)/N(Cc(cc(c(F)c3)F)c3F)C2=O)c2)Cl)c2c1
Target:
SARS-CoV
References
McKimm-Breschkin JL, et al. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227.
Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.